Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting - Fig 2

<p>(A) Kaplan-Meier plot of overall survival analyses among patients with stage IV NSCLC. Note: The median was 294.0 days (95% CI: 277.0, 314.0). (B) Kaplan-Meier plot of overall survival analyses among patients with stage IV NSCLC, by squamous and nonsquamous histology. Note: The median OS was 260.0 days (95% CI: 226, 303.0) for squamous and 304.0 (95% CI: 286.0, 329.0) for nonsquamous NSCLC.</p

Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohorts, by histology and overall.

<p>Induction regimens administered to 1% or more of patients in either squamous or nonsquamous cohorts, by histology and overall.</p

Characteristics of patients presenting with stage IV NSCLC.

<p>Characteristics of patients presenting with stage IV NSCLC.</p

Patient flow chart.

<p>Abbreviations: NSCLC, non-small cell lung cancer; NSCC NOS, non-small cell carcinoma, not otherwise specified.</p

Additional file 1: of Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

Ethics Committee Names and Locations. (XLSX 13 kb